GNH USA

Europe — EMA

Infanrixtetra

GNH USA supplies Infanrixtetra (Diphtheria, tetanus and acellular pertussis vaccine), a vaccine for preventing diphtheria, tetanus and pertussis.

Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis

Request sourcing

1
Pack/s

What is Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis?

Diphtheria and tetanus toxoids and acellular pertussis vaccine, the active ingredient in Infanrixtetra, is a vaccine presented as an injectable solution for intramuscular use. It induces protective immunity against diphtheria, tetanus and pertussis in infants and children as part of routine immunisation schedules.

GNH USA supplies Infanrixtetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for safe delivery.

What is Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis used for?

Infanrixtetra is used to immunise against bacterial toxins and pathogens within the diphtheria‑tetanus‑pertussis (DTP) disease family. - Diphtheria: induces antibodies that neutralise diphtheria toxin, preventing severe respiratory and systemic disease. - Tetanus: stimulates immunity to tetanus toxin, reducing risk of muscle rigidity and spasms after wound exposure. - Pertussis: generates protective antibodies against Bordetella pertussis antigens, decreasing incidence of whooping cough in children.

What are the side effects of Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis?

Infanrixtetra may be associated with local and systemic reactions typical of injectable vaccines.

Common Side Effects: - Pain at injection site: mild to moderate discomfort lasting 1–3 days. - Redness or swelling: localized erythema that resolves within 48 hours. - Low‑grade fever: temperature up to 38 °C occurring within 24 hours. - Fatigue: transient tiredness reported after vaccination. - Headache: mild headache lasting a day or two.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of hives, airway swelling, hypotension. - High fever (>40 °C): persistent fever requiring medical evaluation. - Seizures: rare neurologic events post‑immunisation. - Guillain‑Barré syndrome: extremely rare demyelinating neuropathy. - Persistent crying or inconsolable irritability in infants: may indicate a serious reaction.

What precautions apply to Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis?

Before administering Infanrixtetra, healthcare providers should observe the following precautions. - Contraindication: known severe allergy to any vaccine component, including latex. - Post‑vaccination observation: monitor the patient for at least 15 minutes for immediate reactions. - Fever or acute illness: defer vaccination until the child is afebrile and clinically stable. - Immunocompromised status: assess risk‑benefit, as response may be reduced. - Previous DTP reaction: evaluate severity before repeat dosing. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

What does Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis interact with?

Infanrixtetra can interact with other agents that affect immune function or increase the risk of hypersensitivity.

Major Interactions (Avoid): - Live attenuated vaccines: avoid administration within 4 weeks to prevent interference with immune response. - Immunoglobulin therapy: concurrent use may diminish vaccine efficacy. - Systemic corticosteroids (high dose): may suppress antibody formation.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may mask fever, monitor for underlying reactions. - Antibiotics: generally safe, but monitor for allergic cross‑reactivity if penicillin allergy present. - Blood products: schedule vaccination at least 3 months apart to avoid immune interference.

Frequently asked questions

What is Infanrixtetra used for?+
Infanrixtetra is a combination vaccine that protects against diphtheria, tetanus and pertussis (whooping cough). It is administered as part of routine childhood immunisation programmes to establish active immunity and reduce the incidence of these serious bacterial diseases.
How does the diphtheria and tetanus toxoids and acellular pertussis vaccine work?+
The vaccine contains inactivated toxoids of diphtheria and tetanus together with purified acellular pertussis antigens. After intramuscular injection, the immune system recognises these proteins, activates B‑cells and produces specific IgG antibodies. These antibodies neutralise the toxins and block bacterial attachment, providing long‑lasting protection on future exposure.
What is the usual dose of Infanrixtetra?+
The dose and schedule of Infanrixtetra are determined by the prescribing clinician according to national immunisation guidelines. Typically, the vaccine is given as a single intramuscular injection per dose, with the number of doses depending on the age and vaccination history of the patient.
Is Infanrixtetra safe during pregnancy or breastfeeding?+
Data on use of DTP combination vaccines during pregnancy are limited, and routine vaccination of pregnant women with Infanrixtetra is not recommended unless the potential benefit outweighs any theoretical risk. Breastfeeding is not a contraindication, but the prescriber should evaluate each case individually.
How do I order Infanrixtetra from GNH USA?+
To place an order, submit an enquiry on the Infanrixtetra product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.
How does Infanrixtetra compare with other DTP vaccines?+
Infanrixtetra is an acellular pertussis formulation, which generally causes fewer local reactions than whole‑cell pertussis vaccines. Its diphtheria and tetanus toxoid components are comparable to other licensed DTP products. Efficacy and safety profiles are aligned with European Medicines Agency standards for combination DTP vaccines.
What are the storage and handling requirements for Infanrixtetra?+
Infanrixtetra must be stored refrigerated between 2 °C and 8 °C. It should be kept in the original packaging, protected from light, and must never be frozen or shaken. If temperature excursions occur, the product should be inspected for cloudiness or particulate matter before use.
How is Infanrixtetra administered?+
The vaccine is given by a single intramuscular injection, usually into the anterolateral thigh in infants or the deltoid muscle in older children and adults. Administration should be performed by a qualified healthcare professional using aseptic technique.
What are the most serious risks to watch for after receiving Infanrixtetra?+
Serious adverse events are rare but may include anaphylaxis, high‑grade fever, seizures, or Guillain‑Barré syndrome. Any signs of severe allergic reaction—such as difficulty breathing, swelling of the face or throat, or rapid heartbeat—require immediate medical attention.
Who should not receive Infanrixtetra?+
Infanrixtetra is contraindicated in individuals with a known severe allergy to any of its components, including latex. It should also be avoided in persons who have experienced a severe immediate hypersensitivity reaction after a previous dose of a DTP vaccine.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis
Route
Intramuscular Use
Manufacturer
Laboratoire Glaxosmithkline
Origin
EU